Akers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens
April 08 2020 - 9:25AM
Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer
of rapid health information technologies, today announced that its
collaboration with Premas Biotech has successfully completed a
second milestone, the successful expression of the three
coronavirus antigens, Spike (S), Envelope (E), and Membrane (M),
that were selected for their vaccine candidate. The antigens have
been expressed using the D-CryptTM platform at Premas Biotech,
which utilizes its vectors and S cerevisiae strain. Premas is now
moving forward with purification and post-expression processing,
which we believe should lead to a scaling up of the antigens.
Prabuddha Kundu, Co-Founder and Managing
Director at Premas Biotech, commented, “We are happy to announce
our success in expressing all three antigens. We continue to
believe that the immune system is better served with three shots on
goal and our inclusion of the S, E, and M antigens together should
enhance the efficacy of our vaccine candidate. We are also pleased
with the expedited nature of our milestones thus far, which is a
positive step towards our goal to reach clinical trials.”
Christopher Schreiber, Executive Chairman of
Akers, stated, “We are now halfway through our four-milestone plan
that we believe will allow us to commence clinical trials. Our
partnership with Premas is executing very well and we look forward
to sharing the next milestones as they occur in the weeks to
come.”
About Premas Biotech
Premas Biotech develops novel technologies and
partners with global biopharmaceutical companies to build and
develop novel biotherapeutic & vaccine candidates. Premas' key
focus areas are infectious diseases, cancer, metabolic
disorders and inflammation. Besides D-CryptTM the difficult to
express proteins expression platform, Premas’ leading technologies
include Axtex-4D™: an ex-vivo tissueoid generation platform and
C-Qwence™: a fully human naive India based scFv antibody library.
Further information is available on the Company’s
website: www.premasbiotech.com
Contact email: contact@premasbiotech.com
About Akers Biosciences
Inc.
Akers Biosciences is pursuing the development of
a newly acquired license to a coronavirus vaccine candidate. In
addition, the company develops, manufactures, and supplies rapid,
point of care screening and testing products designed to bring
health related information directly to the patient or clinician in
a timely and cost-efficient manner. Akers has previously announced
that that it had identified the hemp and minor cannabinoid
sectors as promising adjacent opportunities that could benefit from
Akers’ existing facility and its core competencies.
Additional information on the company and its products can be
found at www.akersbio.com.
Forward-Looking Statements
Statements in this press release relating to
plans, strategies, trends, specific activities or investments, and
other statements that are not descriptions of historical facts and
may be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include any risks
detailed from time to time in Akers’ reports filed with the
Securities and Exchange Commission, Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
Forward-looking statements may be identified by terms such as
“may,” “will,” “expects,” “plans,” “intends,” “estimates,”
“potential,” or “continue,” or similar terms or the negative of
these terms. Although Akers believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. Akers does not have any obligation
to update these forward-looking statements other than as required
by law.
Contact:
Investor Relations: Hayden IRBrett Mass,
Managing PartnerPhone: (646)
536-7331Email: brett@haydenir.comwww.haydenir.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024